Please login to the form below

Not currently logged in
Email:
Password:

Novartis completes sale of animal health unit to Lilly

$5.4bn deal is finalised
elanco headquarters animal health lilly

Elanco is Lilly's animal health unit

US pharma company Lilly has completed the acquisition of the animal health business from Swiss rival Novartis.

Novartis announced the sale of the unit in April last year as part of a wider range of deals that included the purchase of GlaxoSmithKline's oncology business in part exchange for its vaccines division and the creation of a joint venture formed from GSK and Novartis' consumer health divisions.

The completion of the deal, worth $5.4bn, strengthens Lilly's own animal health business which operates under the name Elanco.

The company now takes ownership of a unit that achieved mid-single digit growth in the third quarter of 2014, contributing to total consumer health sales of $1.1bn for the period.

In addition to acquiring Novartis' portfolio of animal health products, which include medicines for both pets and livestock, Lilly's Elanco will also take control of new facilities, bringing its capabilities to 17 manufacturing sites and 14 R&D locations.

"As a top-tier animal health company, we are better positioned to help our customers respond to the changing external environment and meet increasing demands for animal protein, as well as growing desires for pet ownership," said Jeff Simmons, president of Elanco Animal Health.

Simmons also highlighted the greater diversification of Elanco, which now looks to have an even split in revenues between products for pets and products for livestock.

As previously announced former head of animal health at Novartis George Gunn will retire now the deal is complete.

Several major pharma companies have reshaped their animal health businesses in the past couple of years.

In 2012 Bayer purchased Teva's animal health division while Sanofi acquired India-based Dosch Pharmaceuticals to boost their respective businesses.

By contrast Pfizer has chosen to distance itself from animal health choosing to spin out its business Zoetis as an independent firm.

Article by
Thomas Meek

8th January 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics